Document is current
Any future updates will be listed below
-
Authors
Michel, Maurice
Schattenberg, Jörn M. https://orcid.org/0000-0002-4224-4703
- License Information
-
More Information
Article History
First Online: 1 September 2025
Competing interests
: M.M. reports consultancy honorary from Ipsen and Boehringer Ingelheim; and speaker honorarium from Ipsen, NovoNordisk, Gilead Sciences, AbbVie, Astra Zeneca and Coliquio. J.M.S. reports consultant honorary from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Boehringer Ingelheim, Boston Pharmaceuticals, Gilead Sciences, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kríya Therapeutics, Eli Lilly, eTherapeutics, Merck, MSD Sharp & Dohme GmbH, Novo Nordisk and Roche; speaker honorarium from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD and Novo Nordisk; and stockholder options with Hepta Bio.
